Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
Awards highlight Avantor's commitment to the Biopharma industry
The stethoscope features high acoustic sensitivity and active noise cancellation, minimizing ambient interference to improve auscultation clarity, particularly in noisy hospital settings
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Subscribe To Our Newsletter & Stay Updated
